FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to medicine and pharmaceutical industry. Pharmaceutical composition has as active substance clozapine and auxiliary substances: hydroxypropylmethylcellulose (HPMC), micro crystalline cellulose modified by silicon dioxide (MCC MSD) and magnesium stearate. Pharmaceutical composition is made in from of coated pills. Coating contains "Opadry II" of Colorcon company or composition, which consists of polyvinyl alcohol, titanium dioxide, polyethylene glucole and acceptable dyes. Pharmaceutical composition of prolonged action based on clozapine has 2 year storage term.
EFFECT: obtaining pharmaceutical composition based on clozapine, relating to group of atypical neuroleptics for treatment of various forms of schizophrenia.
6 cl, 1 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION FOR CORRECTION OF PSYCHOSOMATIC MANIFESTATIONS | 2009 |
|
RU2384336C1 |
| PHARMACEUTICAL COMPOSITION OF PROLONGED ACTION FOR CORRECTION OF PSYCHOSOMATIC MANIFESTATIONS | 2009 |
|
RU2424807C2 |
| METHOD FOR PRODUCTION OF CLOZAPINE PHARMACEUTICAL COMPOSITION IN FORM OF TABLETS AND PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2441651C1 |
| RETARD TABLETS OF TRIMEBUTINE | 2013 |
|
RU2536254C1 |
| AGENT FOR TREATING FUNCTIONAL GASTROINTESTINAL DISEASES | 2020 |
|
RU2740750C1 |
| PHARMACEUTICAL COMPOSITION IN FORM OF HARD PERORAL DRUG FOR TREATMENT OF GASTROINTESTINAL TRACT DISEASES | 2009 |
|
RU2418576C2 |
| NADH COMPOSITION HAVING ANTIOXIDANT PROPERTIES | 2014 |
|
RU2545920C1 |
| METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA WITH USING NEUROLEPTIC COMBINED THERAPY | 2007 |
|
RU2508096C2 |
| METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA WITH USING ATYPICAL NEUROLEPTIC COMBINED THERAPY | 2007 |
|
RU2508106C2 |
| DERIVATIVES OF 7-FLUORO-8-CHLORO-5H-DIBENZO [B, E] [1, 4] DIAZEPINE AND THEIR APPLICATION | 2014 |
|
RU2610169C2 |
